In a remarkable result, CRSP shows that their gene editing treatment, using the CRISPR-Cas9 technology that recently won its co-founder Emmanuelle Charpentier the 2020 Nobel Prize in chemistry, effectively cured one patient of sickle cell anemia and another of B-thalassemia. CRSP announces these results in a talk at the American Society of Hematologists and in a publication in the premier medical journal- NEJM
This is the first time gene editing has cured a genetic disease in patients.
CRSP and the other gene editing stocks EDIT, NTLA, and BEAM have had great runs this year, and their technology has now been validated in a landmark study.
Disclaimer: This information is only for educational purposes. Do not make any investment decisions based on the information in this article. Do you own due diligence or consult your financial professional before making any investment decision.